Proteros biostructures GmbH
Proteros biostructures GmbH: 23rd Conference on Protein Structure Determination in Industry (PSDI) discussing important impact of structural biology for drug discovery

PRESS RELEASE

23^rd Conference on Protein Structure Determination in Industry (PSDI) discussing important impact of structural biology for drug discovery

PSDI conference first time in Germany and organized by Proteros

Martinsried/Munich, Germany – 23 November 2015 – 65 companies and research institutions from 11 countries, including the United States, Japan and Europe, participated in the 23^rd annual international Protein Structure Determination in Industry (PSDI) conference held at Tegernsee, close to Munich. 150 top-class delegates discussed recent developments in the field of structural biology during 45 talks and exhibitor presentations. The meeting took place for the first time in Germany from 8 to 10 November 2015 and was hosted by Proteros.

Nobel Laureate Prof. Robert Huber from the Max Planck Institute for Biochemistry gave the opening lecture on 40 years of pioneering biostructural research and in particular on protease control in health and disease, broadly reviewing the field from its original inception until today.

At the conference, speakers and delegates discussed the scientific state of the art in structure determination, computational chemistry and rational drug design, biophysical characterization of ligand-protein interactions, as well as recent trends in software development, computational design of biopharmaceuticals and X-ray crystallography. Today, more than 110,000 protein and nucleic acid structures have been published, and the current research focus lies mainly on the in-depth analysis of protein-ligand interactions to enable modern drug discovery research.

Attendees emphasized the scientific quality of this year’s PSDI conference and highlighted that biostructural research shows a significant impact for the rational design of modern medicines today. Stephan Krapp, Ph.D., Head of Protein Crystallography at Proteros and PSDI 2015 conference organizer concluded the event by stating: “The passionate talks and discussions during these intense two days have shown once again the significant impact of structural biology for the design of small molecule drugs and biopharmaceuticals and the versatility of new techniques in the field.”

About Proteros biostructures
Proteros, Martinsried/Munich, is a Germany based, privately held biotech company focused on opening gateways to unprecedented targets based on its unique expertise and understanding of protein-small molecule interactions. Co-founded by Nobel Laureate Prof. Robert Huber in 1999, the company is today working for most of the largest pharmaceutical and biotech companies. Proteros is market leader in protein crystallography and provides one of the largest and most powerful platforms for structure guided drug discovery. Proteros has built a pipeline of partnered and proprietary Discovery projects with a strong focus on epigenetic targets. Epigenetic targets are predicted to become one of the fastest growing target classes in Pharma within the next 10 years. More information can be found at www.proteros.com.